Comparison of Visceral Adipokines Visfatin, Vaspin and Omentin Levels in Gestational Diabetes Mellitus Pregnant Women

Completed

• Conditions: Obesity; Visceral Obesity; Gestational Diabetes
• Interventions: Diagnostic Test: oral glucose tolerance test; Diagnostic Test: Blood sample

• Registration Number: NCT05463237
• Lead Sponsor: Siirt University

Brief Summary

The prevalence of maternal obesity is increasing rapidly worldwide and constitutes an important obstetric problem that increases mortality and morbidity in both mothers and infants. Obese women are prone to pregnancy complications such as gestational diabetes mellitus (GDM), and children of obese mothers are more likely to develop cardiovascular and metabolic disease later in life. The risk of developing GDM in obese pregnants is 1.3-3.8 times higher than in pregnant women with a normal body mass index, and approximately 70% of women with GDM remain at risk of developing type 2 diabetes until 28 years postpartum. Gestational diabetes mellitus (GDM) affects approximately 6% of pregnant women and its prevalence is increasing in parallel with the obesity epidemic. GDM is associated with an increased risk of adverse pregnancy outcomes, including macrosomia, preterm delivery, neonatal hypoglycemia, neonatal jaundice, and congenital anomalies. It is also associated with a higher incidence of type 2 diabetes mellitus after birth. It is known that visceral adipose tissue increases in obese women. It is thought that there is a relationship between visceral adipose tissue increase and diabetes. In this study, the levels of new adipocytokines such as Visfatin, Vaspin and Omentin secreted from visceral adipose tissue in patients diagnosed with GDM will be measured.

Detailed Description

The investigators aim in this study the levels of Visfatin, Vaspin and Omentin secreted from this tissue in pregnant women diagnosed with GDM by oral glucose tolerance test (OGTT) between 24-28 weeks of gestation and to determine if there is a relationship between these parameters. For this purpose, , and 87 pregnant women with gestational diabetes diagnosed at 24-28 weeks from the same patient group will be included in the study. . The same number of non-GDM control group pregnant women will also be included in the study at 24-28 weeks. Age, gestational week, pregnancy history (gravida, parity, abortion, missed, ectopic), medical history, preconceptional BMI, current BMI, triglyceride, VLDL, HDL, LDL, cholesterol, HOMA-IR, C-peptide, insulin, Hba1c levels will be saved. In the 2nd trimester, between 24-26 weeks, OGTT will be performed on the patients and the results will be recorded. Visfatin, Vaspin and Omentin levels will be checked and recorded in patients diagnosed with GDM.

Study Timeline

• Study First Submitted: 2022-06-30
• Study First Submitted QC: 2022-07-14
• Study First Posted: 2022-07-18
• Study Start: 2022-10-31
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-24
• Primary Completion: 2023-08-25
• Study Completion: 2023-08-25
• Last Update Posted: 2023-08-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 174

Inclusion Criteria

• >18 years of age
• At the 2.st trimester of pregnancy

Exclusion Criteria

• History of with diabetes mellitus
• Morbidly obese pregnants
• History of abdomen liposuction

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Pregnant women with gestational diabetes(n:87)	Blood sample	Visceral adipokine level will be examined in pregnant women with gestational diabetes.
Control group pregnant (n:87)	oral glucose tolerance test	Visceral adipokine level will be examined in pregnant women with normal pregnant .
Pregnant women with gestational diabetes(n:87)	oral glucose tolerance test	Visceral adipokine level will be examined in pregnant women with gestational diabetes.
Control group pregnant (n:87)	Blood sample	Visceral adipokine level will be examined in pregnant women with normal pregnant .

Primary Outcome Measures

Name	Time	Method
24-28. Visceral Adipokine Levels in Pregnant Women with Gestational Diabetes Between Weeks	Between 24-28 weeks of pregnancy, (an average of 6 months)	VASPIN, VISFATIN, OMENTIN levels will be measured in patients with gestational diabetic,

Trial Locations

Locations (1)

Siirt Üniversity Medical Faculty; 🇹🇷 Siirt, Turkey